Sarepta Therapeutics Inc
(BSP:S1RP34)
R$
37.72
-0.52 (-1.36%)
Market Cap: 72.06 Bil
Enterprise Value: 73.29 Bil
PE Ratio: 78.90
PB Ratio: 9.50
GF Score: 79/100 Sarepta Therapeutics Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript
Nov 12, 2019 / 04:10PM GMT
Martin Douglas Auster;dit Suisse AG
CrÃ;Research Division - Research Analyst
© -
Okay. Hey, everyone, thanks for joining. I'm Marty Auster. I'm the SMID-cap biotech analyst at Crédit Suisse. I've got Doug Ingram, CEO of Sarepta, here with me today. Doug, thanks for coming. Good to see you again.
Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director
Thank you very much. Thank you for having us.
Questions & Answers
Martin Douglas Auster;dit Suisse AG;Douglas S. Ingram
CrÃ;Research Division - Research Analyst;Sarepta
© -
We've got a lot of ground to cover and discuss with Sarepta. There's been a lot of stuff since we've seen you last year, and obviously, you just reported the quarter last week. There's some new news from that as well. So we can maybe kind of -- always good to start with kind of an overview of kind of just framing where the company is at now and kind of where you're leading it.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot